Results 101 to 110 of about 6,026 (204)

Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients [PDF]

Since March 2022, an increase was observed in multidrug-resistant microorganisms (MDRO), associated with the hospital transfer of Ukrainian patients. The goal was to collect phenotypic susceptibility data and assess clinical implications.
, , Bos, Jeroen, de Haan, Angela, den Boer, Hans, Hendrickx, Antoni P.A., Langerak, Diana, Notermans, Daan W., van Westreenen, Mireille, Verkaik, Nelianne J., Vogel, Marius, Wielders, Cornelia C.H., Witteveen, Sandra   +12 more
core   +3 more sources

In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis

Journal of Global Antimicrobial Resistance
: Objectives: Gram-negative pathogens causing respiratory infection in people with cystic fibrosis and bronchiectasis are becoming progressively more resistant to conventional antibiotics. Although cefiderocol is licenced for the treatment of infections
Michael M Tunney, J Stuart Elborn, Chloe S McLaughlin, Christopher M Longshaw   +3 more
doaj   +1 more source

Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol

Scientific Reports
Klebsiella pneumoniae carbapenemase (KPC) is a frequent and widespread carbapenemase, with over 260 variants identified. While KPC often evolves resistance to ceftazidime-avibactam, cefiderocol remains a key treatment option.
Sidonie Hanna, Kevin La, Yutaka Yoshii, Maud Gits-Muselli, Imane El Meouche, Yasmine Benhadid-brahmi, Stéphane Bonacorsi, André Birgy   +7 more
doaj   +1 more source

Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals

Annals of Clinical Microbiology and Antimicrobials
Abstract Background During prolonged FDC therapy, the emergence of FDC non-susceptibility in CRAB has been reported. Here, we report a transmission cluster of FDC-non-susceptible CRAB in four patients, all naïve to FDC treatment, characterized by a premature stop codon and amino acid deletion in the PirA protein.
Alteri, Claudia, Teri, Antonio, Liporace, Maria Francesca, Muscatello, Antonio, Terranova, Leonardo, Schianca, Margherita Carnevale, Salari, Federica, Orena, Beatrice Silvia, Silverj, Flaminia Gentiloni, Bernazzani, Mara, Biscarini, Simona, Renisi, Giulia, Cariani, Lisa, Matinato, Caterina, Canetta, Ciro, Bandera, Alessandra, Callegaro, Annapaola   +16 more
openaire   +3 more sources

High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics [PDF]

To cause infection, bacterial pathogens must overcome host immune factors and barriers to nutrient acquisition. Reproducing these aspects of host physiology in vitro has shown great promise for antibacterial drug discovery.
Brown, Eric D., Brönstrup, Mark, Burrows, Lori L., Chan, Derek C. K., Deisinger, Julia P., Hilker, Simon, Ives, Rowan, Magolan, Jakob, Peukert, Carsten, Raivio, Tracy L., Ritchie, Nikki E., Weber, Brent S., Årdal, Christine   +12 more
core   +2 more sources

Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient

Microbiology Spectrum
Pseudomonas aeruginosa is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing P.
Joaquim Viñes, Sabina Herrera, Andrea Vergara, Ignasi Roca, Jordi Vila, Tommaso Francesco Aiello, José Antonio Martínez, Ana del Río, Carlos Lopera, Carolina Garcia-Vidal, Climent Casals-Pascual, Àlex Soriano, Cristina Pitart   +12 more
doaj   +1 more source

In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form–alone and in combination with bacteriophages

Scientific Reports
Multi-drug resistant Gram-negative pathogens are increasingly difficult-to-treat perpetrators of infections. New, innovative, and more multifaceted therapies for the treatment of multi-drug resistant strains are thus urgent to hinder further drug ...
Rima Fanaei Pirlar, Nexhmije Halili, Tina Travnik, Andrej Trampuz, Svetlana Karbysheva   +4 more
doaj   +1 more source

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians [PDF]

, 2022
Corcione, Silvia, De Rosa, Francesco, Di Bella, Stefano, Lupia, Tommaso, Stroffolini, Giacomo   +4 more
core   +1 more source

Cefiderocol. Summary and conclusions

Revista Española de Quimioterapia, 2022
Mensa, José, Barberán, José
openaire   +2 more sources

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective [PDF]

, 2021
Corcione, S., De Rosa, F. G., Lupia, T.
core   +1 more source